ICER casts doubt on Sarepta’s DMD gene therapy
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning! A crowdsourced Readout today, to be sure, with contributions from STAT’s Jason Mast, Elaine Chen, and Jonathan Wosen. We get into earnings from Novo Nordisk, Amgen, and Illumina, and see that ICER is not so enthused about a gene therapy from Sarepta.
Read Original Article: ICER casts doubt on Sarepta’s DMD gene therapy »
